Lubiprostone

• Chronic Idiopathic Constipation
• Irritable Bowel Syndrome with Constipation
• Opioid-Induced Constipation

Lubiprostone (Amitiza) is an oral medication used to treat chronic idiopathic constipation, irritable bowel syndrome with constipation in adult women, and opioid-induced constipation in adults with chronic non-cancer pain. As the first medication in its class, it offered an alternative for patients whose symptoms persist despite fiber, hydration, osmotic laxatives, and stimulant agents. Rather than drawing fluid from outside the gut or stimulating bowel contractions directly, lubiprostone activates a specific intestinal chloride channel to soften stool, normalize transit, and restore predictable bowel movements. It is used by primary care and gastrointestinal clinicians as part of a stepped approach to chronic constipation.

Mechanism of Action

Lubiprostone is a bicyclic fatty acid derived from prostaglandin E1. Unlike systemic prostaglandins, it acts locally and selectively. The molecule binds to and activates type 2 chloride channels (ClC-2) located on the apical membrane of intestinal epithelial cells. Activation of these channels increases chloride efflux into the intestinal lumen. Sodium and water follow passively to maintain electroneutrality and osmotic balance, increasing the luminal fluid that softens stool and accelerates transit. The mechanism is restricted to the gut surface, so serum electrolytes and pH remain essentially unchanged.

Because lubiprostone has minimal systemic absorption, plasma concentrations of the parent compound are below the limit of quantification in most patients. Its active metabolite, M3, is detectable but cleared rapidly. This pharmacology explains the favorable interaction profile and the limited need for dose adjustment in renal impairment. Lubiprostone is not a stimulant and does not depend on enteric neuron activation, distinguishing it from senna or bisacodyl. Patients do not develop the dependence sometimes attributed to chronic stimulant laxative use. Onset of effect is generally within 24 hours of the first dose, though full benefit may take several days. The most common adverse effect, nausea, is dose related and arises in part from gastric distention from increased intraluminal fluid; taking the medication with food substantially reduces this complaint.

Clinical Use

Lubiprostone is positioned as a second-line agent for chronic constipation according to the American Gastroenterological Association guidelines, after dietary fiber, adequate fluid, and osmotic agents such as polyethylene glycol have been tried. It is reasonable to consider in patients who have failed osmotic laxatives, who experience cramping with stimulant agents, or who have IBS with constipation where bloating and pain accompany infrequent bowel movements. Within the prescription class, it competes with linaclotide and plecanatide, which work through guanylate cyclase-C activation, and with prucalopride, a 5-HT4 agonist that accelerates colonic transit. Choice depends on symptom pattern, insurance coverage, and tolerance.

Lubiprostone is also approved for opioid-induced constipation in patients with chronic non-cancer pain, where bowel motility is suppressed by mu-opioid receptor activation in the enteric nervous system. Comparative effectiveness in this setting is similar to peripherally acting mu-opioid receptor antagonists such as naloxegol or methylnaltrexone, though the choice often hinges on whether patients also have baseline constipation independent of opioids. Patient selection should exclude those with mechanical obstruction, severe diarrhea, or known hypersensitivity to the drug. Our overview of stress affects gut: brain-gut connection discusses lifestyle factors that influence chronic constipation symptoms.

How to Take It

Lubiprostone is dosed twice daily with food and water. The standard dose for chronic idiopathic constipation and opioid-induced constipation is 24 mcg twice daily. For IBS with constipation in adult women, the lower 8 mcg twice daily dose is used. Capsules should be swallowed whole, not chewed or split, because they are coated to reach the small intestine intact. Taking with food, particularly something containing fat, reduces nausea by slowing gastric emptying. Adequate hydration enhances the response.

A missed dose should be skipped if the next dose is within a few hours; do not double up. Storage at room temperature in the original container is appropriate. During the first week patients may notice nausea, mild abdominal cramping, soft stools, or transient headache. Nausea is the most frequent reason for discontinuation; many patients tolerate the lower 8 mcg dose if needed, and reassessment of timing relative to meals can help. Bowel movements typically normalize within several days. If diarrhea becomes severe or persistent, the dose should be paused and the office contacted. Patients should not combine lubiprostone with other prescription chronic constipation agents without medical guidance.

Monitoring and Follow-Up

Before starting therapy, mechanical obstruction must be reasonably excluded based on history, examination, and, when appropriate, imaging. Alarm features such as unintentional weight loss, hematochezia, family history of colon cancer, new-onset constipation after age 50, or failure to thrive deserve workup, often including colonoscopy per USPSTF screening criteria. Baseline symptom scores using a validated bowel diary or Bristol Stool Scale establish a starting point.

Follow-up in two to four weeks evaluates response, side effect tolerance, and adherence. A meaningful response includes at least one additional spontaneous bowel movement per week, reduction in straining, and improved stool form. If nausea limits use, dose reduction or a trial of an alternative such as linaclotide or polyethylene glycol may be appropriate. Long-term use is reasonable as long as benefit continues; periodic medication reviews every six to twelve months ensure ongoing need. Red numbers include severe persistent diarrhea with dehydration, syncope after a dose, or new abdominal pain with distention that could suggest obstruction. Electrolyte panels are not routinely required given minimal systemic absorption but should be checked if diarrhea is severe.

Special Populations

Elderly patients tolerate lubiprostone but may be more sensitive to nausea and dehydration; the 24 mcg twice daily dose is appropriate but lower titration is reasonable. Patients with moderate hepatic impairment should start at 16 mcg twice daily, and those with severe hepatic impairment (Child-Pugh C) should start at 8 mcg twice daily for chronic idiopathic constipation, with similar reductions for the IBS-C indication. No dose adjustment is required for renal impairment. Pregnancy data in humans are limited, and animal studies suggest possible fetal loss at high doses. Women of childbearing potential should have a negative pregnancy test before starting and use effective contraception. The medication is generally avoided during pregnancy unless clearly needed. It is not known whether lubiprostone is excreted in human breast milk; alternative agents such as polyethylene glycol are usually preferred during lactation. Pediatric safety has not been established. Patients with severe diarrhea at baseline should not begin therapy until that resolves. Those with cystic fibrosis or other chronic intestinal inflammation may experience exaggerated responses.

When to Contact Your Doctor

Call the office for severe or persistent diarrhea lasting more than two days, signs of dehydration including dizziness, dark urine or reduced urine output, syncope after dosing, or significant abdominal pain with distention. Sudden shortness of breath after a dose, sometimes called dyspnea reactions, has been reported and warrants discontinuation and evaluation. New rectal bleeding, weight loss, or change in stool caliber needs assessment to exclude colorectal pathology, particularly in patients over 45 who have not yet had appropriate screening per National Cancer Institute recommendations. Pregnancy or planned pregnancy should prompt medication review.

Chronic constipation is more common than many patients realize, particularly in older adults, women, patients on opioids for chronic pain, and those with limited mobility or low fluid intake. In our warm climate, dehydration during summer months can worsen baseline constipation and reduce the effectiveness of any laxative regimen. A daily fluid target of roughly two to three liters, regular physical activity, and adequate dietary fiber from fruits, vegetables, and whole grains form the foundation. When prescription therapy is needed, a structured trial of one agent at a time, with a clear plan for assessment after two to four weeks, helps determine which medication suits an individual. Patients should be reassured that lubiprostone does not cause dependence or laxative tolerance, so long-term use is reasonable when continued benefit is documented. Coordination with the prescribing clinician on the role of probiotics, prebiotics, magnesium-containing antacids, and over-the-counter laxatives helps avoid duplication and side effects.

If chronic constipation is interfering with comfort, energy, or quality of life despite over-the-counter treatments, our internal medicine team can help refine the diagnosis and choose among prescription options. Contact us or schedule a visit for a tailored plan.